0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
This Month in Archives of Neurology |

This Month in Archives of Neurology FREE

Arch Neurol. 2009;66(10):1190-1191. doi:10.1001/archneurol.2009.222.
Text Size: A A A
Published online

ATAXIA: CHANNELING CHANGES INTO NOVEL THERAPIES

Shakkottai and PaulsonArticle provide a clear and direct discussion suggesting that neuronal dysfunction stemming from perturbed channel activity likely explains some motor deficits in episodic and degenerative ataxias. Importantly, they point out that understanding these physiologic changes may reveal novel therapeutic targets for symptomatic treatment of ataxia. New ideas, new strategies, and potential new therapeutic approaches are presented in this important review.

ESSENTIAL TREMORS

LouisArticle reviews the facts related to the present understanding of essential tremor, the most common pathological tremor in humans. He provides evidence that essential tremor is a family of diseases rather than a single entity.

STRATEGIES FOR THE PREVENTION OF DEMENTIA

Middleton and YaffeArticle emphasize that, for the foreseeable future, risk factor modification remains the cornerstone of dementia prevention including vascular risk factor control, cognitive activity, physical activity, social engagement, diet, and recognition of depression.

INTERFERON-BETA THERAPY ENHANCES CYTOKINE EXPRESSION IN MULTIPLE SCLEROSIS

Cepok and colleaguesArticle demonstrate that interferon-beta strongly upregulates a set of cytokines and CCR1 in peripheral immune cells. The upregulation of these chemokines may reduce chemoattraction of immune cells into the central nervous system and add to the therapeutic effects of interferon-beta. Editorial perspective is provided by Olaf Stüve, MD, PhD, and Richard M. Ransohoff, MD.Article

MODELING PREDICTS THAT EPILEPSY MAY BE CAUSED BY VERY SMALL FUNCTIONAL CHANGES IN ION CHANNELS

Thomas et alArticle describe how statistical power calculations indicate that small changes in ion channels are effectively undetectable with current experimental practices, thus posing new challenges for the functional analysis and validation of epilepsy genes. This article provides an important paradigm shift in our thinking regarding detection of genetically basic channelopathies that cause epilepsy.

SEIZURE RELAPSE AND DRUG RESISTANCE FOLLOWING LONG-TERM SEIZURE REMISSION

SchillerArticle reports that about half of patients who entered long-term seizure remissions experienced seizure relapse, and more than a quarter of patients eventually developed drug resistance. Treatment history served as a significant independent predictive risk factor for seizure relapse and development of drug resistance.

Place holder to copy figure label and caption

Seizure relapse and development of drug-resistant epilepsy in patients who entered long-term (>1 year) seizure remissions. The average percentages of patients who were seizure free and drug responsive are plotted as a function of time from the onset of the antiepileptic drug–induced seizure remission. The experimental points were fitted with monoexponential functions (lines), with minimal values of 56.4% for seizure relapses and 72.6% for development of drug resistance and a half-decay time constant of 21.5 months for both curves.

Graphic Jump Location

CODISTRIBUTION OF AMYLOID Β PLAQUES AND SPONGIFORM DEGENERATION IN FAMILIAL CREUTZFELDT-JAKOB DISEASE

Ghoshal and colleaguesArticle provide the first description of amyloid β (Aβ) pathology in familial Creutzfeldt-Jakob disease with the E200K mutation. This observation suggests that the prion protein plays a central role in Aβ formation and that Aβ pathology and prion disease likely influence each other.

TEN-YEAR CHANGE IN PLASMA AMYLOID Β LEVELS AND LATE-LIFE COGNITIVE DECLINE

Okereke et alArticle suggest that higher plasma amyloid β (Aβ)–40 to Aβ42 ratios in late-midlife and increases in Aβ40 to Aβ42 10 years later were significantly associated with greater decline in global cognition in late life.

LONGITUDINAL STUDY OF THE TRANSITION FROM HEALTHY AGING TO ALZHEIMER DISEASE

Johnson and colleaguesArticle describe that there is a sharp inflection point followed by accelerating decline in multiple domains of cognition, not just memory, in the preclinical period of Alzheimer disease, when there is insufficient cognitive decline to warrant a clinical diagnosis of Alzheimer disease using conventional criteria. These significant findings emphasize that research into early detection of cognitive disorders using only episodic memory tasks may not be sensitive to all early manifestations of the disease.

SEX AND SORL1 VARIANTS IN ALZHEIMER DISEASE

Cellini et alArticle confirm the association of SORL1 with Alzheimer disease, showing a possible effect of sex, and suggest that this gene may be a promising susceptibility factor in late-onset Alzheimer disease.

INTRONIC VARIANTS OF BTBD9 GENE AND TOURETTE SYNDROME

Rivière and colleaguesArticle provide evidence that variants in BTBD9 that predispose patients to restless legs syndrome and periodic limb movements during sleep are also associated with Tourette syndrome, particularly Tourette syndrome without obsessive-compulsive disorder.

IDEOMOTOR APRAXIA AND CORTICOBASAL SYNDROME

Huey et alArticle report that in corticobasal syndrome, patients' ideomotor apraxia is associated with left posterior frontal cortical and subcortical volume loss.

Figures

Place holder to copy figure label and caption

Seizure relapse and development of drug-resistant epilepsy in patients who entered long-term (>1 year) seizure remissions. The average percentages of patients who were seizure free and drug responsive are plotted as a function of time from the onset of the antiepileptic drug–induced seizure remission. The experimental points were fitted with monoexponential functions (lines), with minimal values of 56.4% for seizure relapses and 72.6% for development of drug resistance and a half-decay time constant of 21.5 months for both curves.

Graphic Jump Location

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

366 Views
0 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs